

# Stroke

## ORIGINAL CONTRIBUTION

# Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities

AQ1

Nicola J. Armstrong, PhD\*; Karen A. Mather, PhD\*; Muralidharan Sargurupremraj, PhD\*; Maria J. Knol, MSc; Rainer Malik, PhD; Claudia L. Satizabal, PhD; Lisa R. Yanek, MPH; Wei Wen, PhD; Vilmondur G. Gudnason, MD, PhD; Nicole D. Dueker, PhD; Lloyd T. Elliott, PhD; Edith Hofer, PhD; Joshua Bis, PhD; Neda Jahanshad, PhD; Shuo Li, MSc; Mark A. Logue, PhD; Michelle Luciano, PhD; Markus Scholz, PhD; Albert V. Smith, PhD; Stella S. Tringali, PhD; Dina Vojinovic, PhD; Rui Xia, PhD; Fidel Alfaro-Almagro, MSc; David Ames, MD; Najaf Amin, PhD; Philippe Amouyel, MD, PhD; Alexa S. Beiser, PhD; Henry Brodaty, DSc; Ian J. Deary, PhD; Christine Fennema-Notestine, PhD; Piyush G. Gampawar, MSc; Rebecca Gottesman, MD, PhD; Ludovica Griffanti, PhD; Clifford R. Jack, Jr, MD; Mark Jenkinson, PhD; Jiyang Jiang, PhD; Brian G. Kral, MD, MPH; John B. Kwok, PhD; Leonie Lampe, MD; David C.M. Liewald, BSc; Pauline Maillard, PhD; Jonathan Marchini, PhD; Mark E. Bastin, PhD; Bernard Mazoyer, MD, PhD; Lukas Pirpamer, MSc; José Rafael Romero, MD; Gennady V. Roshchupkin, PhD; Peter R. Schofield, PhD; Matthias L. Schroeter, MD, PhD; David J. Stott, PhD; Anubalam Thalamuthu, PhD; Julian Trollor, MD; Christophe Tzourio, MD; Jeroen van der Grond, PhD; Meike W. Vernooij, MD, PhD; Veronica A. Witte, PhD; Margaret J. Wright, PhD; Qiong Yang, PhD; Zoe Morris, MBBS; Siggvi Siggurdsson, MSc; Bruce Psaty, MD; Arno Villringer, MD; Helena Schmidt, MD, PhD; Asta K. Haberg, MD, PhD; Cornelia M. van Duijn, PhD; J. Wouter Jukema, PhD; Martin Dichgans, MD; Ralph L. Sacco, MD; Clinton B. Wright, MD; William S. Kremen, PhD; Lewis C. Becker, MD; Paul M. Thompson, PhD; Thomas H. Mosley, PhD; Joanna M. Wardlaw, MD; M. Arfan Ikram, MD, PhD; Hieab H.H. Adams, MD, PhD; Sudha Seshadri, MD; Perminder S. Sachdev, MD; Stephen M. Smith, PhD; Lenore Launer, PhD†; William Longstreth, MD†; Charles DeCarli, MD†; Reinhold Schmidt, MD†; Myriam Fornage, PhD†; Stephanie Debette, MD, PhD†; Paul A. Nyquist<sup>‡</sup>, MD, MPH†

AQ3

**BACKGROUND AND PURPOSE:** Periventricular white matter hyperintensities (WMH; PVWMH) and deep WMH (DWMH) are regional classifications of WMH and reflect proposed differences in cause. In the first study, to date, we undertook genome-wide association analyses of DWMH and PVWMH to show that these phenotypes have different genetic underpinnings.

AQ4

**METHODS:** Participants were aged 45 years and older, free of stroke and dementia. We conducted genome-wide association analyses of PVWMH and DWMH in 26,654 participants from CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology), ENIGMA (Enhancing Neuro-Imaging Genetics Through Meta-Analysis) and the UKB (UK Biobank). Regional correlations were investigated using the genome-wide association analyses -pairwise method. Cross-trait genetic correlations between PVWMH, DWMH, stroke, and dementia were estimated using LDSC.

AQ5

**RESULTS:** In the discovery and replication analysis, for PVWMH only, we found associations on chromosomes 2 (*NBEAL*), 10q23.1 (*TSPAN14/FAM231A*), and 10q24.33 (*SH3PXD2A*). In the much larger combined meta-analysis of all cohorts, we identified ten significant regions for PVWMH: chromosomes 2 (3 regions), 6, 7, 10 (2 regions), 13, 16, and 17q23.1. New loci of interest include 7q36.1 (*NOS3*) and 16q24.2. In both the discovery/replication and combined analysis, we found genome-wide significant associations for the 17q25.1 locus for both DWMH and PVWMH. Using gene-based association analysis,

Correspondence to: Paul A Nyquist, MD, MPH, 416 Phipps, 600 N Wolfe St, Baltimore, MD 21287. Email pnyquist1@jhmi.edu

\*Drs Armstrong, Mather, and Sargurupremraj shared first authorship.

†Drs Launer, Longstreth, DeCarli, Reinhold Schmidt, Fornage, Debette, and Nyquist shared senior authorship.

This manuscript was sent to Eric E. Smith, MD, MPH, Guest Editor, for review by expert referees, editorial decision, and final disposition.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.119.027544>.

For Sources of Funding and Disclosures, see page xxx.

© 2020 American Heart Association, Inc.

Stroke is available at [www.ahajournals.org/journal/str](http://www.ahajournals.org/journal/str)

19 genes across all regions were identified for PVWMH only, including the new genes: *CALCRL* (2q32.1), *KLHL24* (3q27.1), *VCAN* (5q27.1), and *POLR2F* (22q13.1). Thirteen genes in the 17q25.1 locus were significant for both phenotypes. More extensive genetic correlations were observed for PVWMH with small vessel ischemic stroke. There were no associations with dementia for either phenotype.

**CONCLUSIONS:** Our study confirms these phenotypes have distinct and also shared genetic architectures. Genetic analyses indicated PVWMH was more associated with ischemic stroke whilst DWMH loci were implicated in vascular, astrocyte, and neuronal function. Our study confirms these phenotypes are distinct neuroimaging classifications and identifies new candidate genes associated with PVWMH only.

**Key Words:** brain ■ genome-wide association study ■ neuroimaging ■ risk factors ■ white matter

## Nonstandard Abbreviations and Acronyms

<b>CHARGE</b>	Cohorts for Heart and Aging Research in Genomic Epidemiology
<b>DWMH</b>	deep WMH
<b>ENIGMA</b>	Enhancing Neuro-Imaging Genetics Through Meta-Analysis
<b>GWAS</b>	genome-wide association analyses
<b>PVWMH</b>	periventricular WMH
<b>SVD</b>	small vessel disease
<b>UKB</b>	UK Biobank
<b>WMH</b>	white matter hyperintensities

**R**adiological white matter hyperintensities (WMH) of presumed ischemic origin are the most prevalent sign of cerebral small vessel disease (SVD) and represent 40% of all SVD disease burden.<sup>1</sup> They are detected as incidental lesions on T2-weighted magnetic resonance imaging.<sup>1</sup> WMH are associated with increased risk for ischemic and hemorrhagic stroke, cognitive decline, and motor gait disorders.<sup>2–6</sup> Two regional classifications, based on their anatomic relationship to the lateral ventricles in the brain, are periventricular WMH (PVWMH) and deep WMH (DWMH).<sup>5,7–9</sup> PVWMH have been associated with declines in cognitive performance and increased systolic and arterial pressure, whereas DWMH are linked to body mass index, mood disorders, gait impairment, and arterial hypertension.<sup>10–12</sup> This categorization reflects proposed differences in underlying pathophysiology.<sup>5,7,8</sup> DWMH lesions occur in the sub-cortex, areas primarily supplied by long microvessels, with lower estimated blood pressures, possibly subject to damage secondary to hypertension and possibly with consequent hypoperfusion.<sup>1,8,13,14</sup> PVWMH are related to alterations in short penetrating microvessels ending in close approximation to larger arterial blood vessels with different vascular architecture such as 2 leptomeningeal layers and enlarged perivascular spaces.<sup>1,15</sup> They are hypothesized to be affected more directly by hypertension and risk factors associated with stroke.<sup>1,8,13,14</sup>

These subclassifications may also reflect differences in associated underlying genetic factors.<sup>16</sup> Twin and family studies report that both PVWMH and DWMH have high heritability and genetic correlations.<sup>16,17</sup> Recently, genome-wide association analyses (GWAS) for total WMH volume identified a major genetic risk locus on chromosome 17q25.1<sup>18–21</sup> and several other loci (eg, 10q24, 2p21, 2q33, 6q25.1).<sup>19,21,22</sup> However, the genetic determinants of regional WMH burden, specifically DWMH and PVWMH, remain elusive.

We combined all available participants aged 45 and above with both DWMH and PVWMH measurements from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) and the ENIGMA (Enhancing Neuro-Imaging Genetics Through Meta-Analysis) consortia, and the UKB (UK Biobank). This is the only GWAS to date examining WMH subclassifications. We hypothesized that separating the two WMH subclassifications would mitigate phenotype heterogeneity, allowing us to identify additional risk loci and show that DWMH and PVWMH have different genetic underpinnings and pathophysiology.

## MATERIALS AND METHODS

Summary data for this meta-analysis will be available through the database of Genotypes and Phenotypes Cohorts for Heart and Aging Research in Genomic Epidemiology Summary Results site, which can be downloaded via authorized access.

### Study Cohorts

Study participants (total N=26 654) were drawn from cohorts in the CHARGE and ENIGMA consortia and the UKB. Detailed methods are in the [Data Supplement](#). All cohorts followed standardized procedures for participant inclusion, genotype calling, phenotype harmonization, covariate selection, and study-level analysis. Participants were included if they had phenotype, genotype, and covariate data available and were aged 45 years and over without stroke, dementia, or any neurological abnormality at the time of magnetic resonance imaging scanning. All participants provided written informed consent, and each study received ethical approval to undertake this work.

## Phenotype and Covariates

The magnetic resonance imaging and WMH extraction methods for each study are detailed in the [Data Supplement](#). In brief, PVWMH and DWMH volumetric data were extracted using automated methods for all studies except HUNT, LBC, and AGES, which used visual rating scales (Table I in the [Data Supplement](#)). Hypertension was defined as systolic blood pressure  $\geq 140$  mmHg and diastolic blood pressure  $\geq 90$  mmHg or on current antihypertensive treatment.

## Statistical Analysis

Each study fitted linear regression models to test the association of DWMH and PVWMH (continuous measures) with individual genetic variants. Age, sex, and ICV were assumed, and the models were adjusted for age (years), sex, and ICV (where applicable). In addition, principal components for population stratification and other covariates, such as familial structure, were included if necessary. Models were also fitted with hypertension as an additional covariate.

Fixed-effects, inverse variance-weighted meta-analysis was carried out in METAL,<sup>23</sup> with correction for genomic control. Two meta-analyses were carried out: all cohorts excluding UKB (discovery, phase I) and all cohorts (phase II). Post meta-analysis QC was also performed (see in the [Data Supplement](#)).

## Genetic Correlations With Stroke and Dementia

Cross-trait genetic correlation between the 2 subclassifications of WMH, stroke, and dementia was estimated using LDSC<sup>24</sup> on the GWAS summary statistics from phase II, MEGASTROKE (European ancestry only).<sup>25</sup> Linkage disequilibrium scores were based on the HapMap3 European reference panel. Regional level correlation was investigated using the GWAS-PW and HESS methods.<sup>26,27</sup>

## RESULTS

Detailed study descriptions are provided in Tables I through III in the [Data Supplement](#). The discovery cohort was comprised of  $\approx 18234$  older adults ( $\geq 45$  years, 16 studies) and was primarily white, with 736 blacks and 658 Hispanics. The predominantly white UKB was used as the replication cohort ( $n=8428$ ).


In the discovery analysis (phase I), genome-wide significant associations ( $P < 5 \times 10^{-8}$ ) were observed in the 17q25.1 region for both phenotypes (Tables IV and V in the [Data Supplement](#)). Only the PVWMH analysis found additional genome-wide significant associations on chromosomes 2 and 10 (2 regions). Two of these regions had previously been described for total WMH burden (chromosomes 2, *NBEAL*,<sup>19,21</sup> 10q24.33, *SH3PXD2A*<sup>21</sup>), whereas 10q23.1 had not been described. Adjusting for hypertension made little difference to our findings (Tables VI through VII in the [Data Supplement](#)). Replication of the majority of genome-wide significant results for both phenotypes was observed after adjustment for multiple testing (DWMH  $P < 3.6 \times 10^{-4}$ , PVWMH  $P < 2.76 \times 10^{-4}$ , Tables VIII and IX in the [Data Supplement](#)).

Given the relatively large size of the replication cohort, a combined meta-analysis (phase II) was undertaken using all samples ( $n=1654$ ). Removing either the small subsample of nonwhites or the cohorts with visual ratings did not substantially change the findings (beta value  $r^2 > 0.93$ ). The phase II GWAS meta-analyses identified 236 for DWMH and 513 genome-wide significant SNPs for PVWMH (Figure 1A, Table 1, Tables X and XI in the [Data Supplement](#), respectively). Figure 1B shows the zoom plot of the single locus identified for DWMH on chr17q25.1. The associations of the identified genome-wide and suggestive associations for each phenotype for the alternate trait are also provided in Tables X and XI in the [Data Supplement](#). The only SNPs genome-wide significant for both phenotypes ( $n=209$ ) were located on 17q25.1 (Figure 2A).

Ten chromosomal regions containing 290 genome-wide significant SNPs for PVWMH only were identified on chromosomes 2 (3 regions), 6, 7, 10 (2 regions), 13, 16, and 17q23.1 (Results, Table XI, and Figures I and II in the [Data Supplement](#)). Four loci had not been previously reported for associations with total WMH at the genome-wide significant level: (1) 7q36.1 (7.2 kb) containing 2 exonic SNPs in the *NOS3* gene; (2) 10q23.1 (50.5 kb) containing 4 intronic SNPs in *TSPAN14* & *FAM231A*; (3) 16q24.2 (1.2 kb) containing 2 intergenic SNPs; (4) 17q21.31 (27.2 kb) containing 8 SNPs, most of which are intronic and in the *NMT1* gene. Many of these are [expression quantitative trait loci](#) (Figure 2B). Further descriptions of the PVWMH findings are found in the Results in the [Data Supplement](#).

As expected, the association of the 17q25.1 locus with both phenotypes was confirmed. The size of this region, including genome-wide significant SNPs only, was similar for both DWMH (236 SNPs, BP 73757836-74025656, Figure 1B) and PVWMH (223 SNPs, BP 73757836-74024711, Figure 1A in the [Data Supplement](#)). The top results in this locus were rs3744020 for DWMH ( $P=7.06 \times 10^{-35}$ , *TRIM47* intronic SNP) and rs35392904 for PVWMH ( $P=3.989 \times 10^{-28}$ , *TRIM65* intronic SNP), which are in high linkage disequilibrium ( $R^2=0.902$ ; Table 1). Many of these SNPs are eQTLs or have long-range chromatin interactions (Figure 2B and 2C). For further details, see the Results in the [Data Supplement](#).

Using gene-based tests, 13 genes in the 17q25.1 locus reached genome-wide significance ( $P < 2.66 \times 10^{-6}$ ) with both phenotypes (Table 2, Figure 2D, Tables XII and XIII in the [Data Supplement](#)). For PVWMH, an additional 19 genes were identified, covering the majority of regions/loci found in the SNP-based analysis (Figure 2D, Table 2, Table XIII in the [Data Supplement](#)). Four genes were located in previously unidentified regions: *CALCRL* (2q32.1), *KLHL24* (3q27.1), *VCAN* (5q27.1), and *POLR2F* (22q13.1).



**Figure 1. A, Phase II genome-wide association analyses meta-analysis.**

Miami plot for periventricular white matter hyperintensities (PVWMH; **upper**) and deep white matter hyperintensities (DWMH; **lower**). Dashed line shows genome-wide significance threshold ( $P < 5 \times 10^{-8}$ ). **B**, Chromosome 17 regional plot of genome-wide significant SNPs for DWMH. Colors of the SNPs indicate the level of linkage disequilibrium with the top SNP (purple), rs35392904.

Heritability analyses revealed low to moderate heritability for both traits (see Results in the [Data Supplement](#)). A high genetic correlation between DWMH and PVWMH was observed ( $r_g = 0.927$ ,  $P = 1.1 \times 10^{-65}$ ), indicating a shared genetic architecture. Figure 3 shows the genetic correlations with DWMH, PVWMH, stroke, and Alzheimer disease. Positive genetic correlations with both phenotypes were found for all stroke, ischemic stroke, and SVD.

Intracerebral hemorrhage (all types) was correlated with DWMH only. No significant correlations were found with Alzheimer disease (Table XIV in the [Data Supplement](#)).

Using GWAS-PW,<sup>26</sup> we observed several regions with high probability ( $>90\%$ ) for harboring a shared genetic variant between PVWMH and DWMH (Table XV in the [Data Supplement](#)). These regions encompass several genome-wide significant loci that were identified

AQ13  
AQ14  
AQ15

AQ18



**Table 1. Top Genome-Wide Significant SNP Results From Each Genomic Locus Identified From the Phase II GWAS Meta-Analysis for Deep and PV WMH**

WMH	rsID	CHR	POS	Nearest Gene	Function/Position	A1	A2	Freq (A1)	Beta (SE)	N	Direction	P Value
PV	rs3744020	17q25.1	73871773	TRIM47	Intronic	A	G	0.1897	0.0899 (0.0073)	26 438	+++++?++++ +++++-----	7.06×10 <sup>-35</sup>
Deep	rs35392904	17q25.1	73883918	TRIM65	Intronic	T	C	0.7981	-0.0765 (0.0070)	26 642	-----+ -----+	3.99×10 <sup>-28</sup>
PV	rs3758575	10q24.33	105454881	SH3PXD2A	Intronic	A	G	0.4904	0.0388 (0.0058)	26 654	+++++----- +++++-----	2.00×10 <sup>-11</sup>
PV*	rs12928520	16q24.2	87237568	C16orf95	Intergenic	T	C	0.4252	0.0431 (0.0065)	26 327	+++++?+--- +++++-----	4.22×10 <sup>-11</sup>
PV	rs275350	6q25.1	151016058	PLEKHG1	Intronic	C	G	0.4202	0.0374 (0.0057)	26 654	+-----+ +++++-----	4.86×10 <sup>-11</sup>
PV	rs7596872	2p16.1	56128091	EFEMP1	Intronic	A	C	0.0975	0.0642 (0.0099)	25 730	-----+ -----??+----	8.66×10 <sup>-11</sup>
PV	rs72934583	2q33.2	204009057	NBEAL1	Intronic	T	G	0.8740	0.0529 (0.0087)	25 730	-----+ +++??+-----	1.03×10 <sup>-9</sup>
PV	rs57242328	2p21	43073247	AC098824.6	Intergenic	A	G	0.3317	-0.0368 (0.0061)	25 730	-----+ -----??+-----	1.85×10 <sup>-9</sup>
PV*	rs7213273	17q21.31	43155914	NMT1	Intronic	A	G	0.6668	0.0341 (0.0059)	26 111	+++++?+--- ++-----	8.89×10 <sup>-9</sup>
PV*	rs1993484	10q23.1	82222698	TSPAN14	Intronic	T	C	0.2388	0.0378 (0.0067)	26 654	+++++----- ++-----	1.36×10 <sup>-8</sup>
PV	rs11838776	13q34	111040681	COL4A2	Intronic	A	G	0.2793	0.0350	26 654	-----+ +++++-----	2.82×10 <sup>-8</sup>
PV*	rs1799983	7q36.1	150696111	NOS3	Exonic	T	G	0.3201	0.0373	26 654	+++++----- ++-----	3.68×10 <sup>-8</sup>

Effect allele is A1. A1 indicates allele 1; A2, allele 2; Chr, chromosome; GWAS, genome-wide association analyses; PV, periventricular; WMH, white matter hyperintensities.

\*Those loci have not been previously associated with total WMH.

for PVWMH (2p16.1 [*EFEMP1*], 2q33.2 [*CARF* and *NBEAL1*], 6q25.1 [*PLEKHG1*], 16q24.2 [*C16orf95*], and 17q25.1 [*TRIM47*, *TRIM65*]). Additionally, by using HESS,<sup>27</sup> regional level correlation estimates were derived for those regions identified by the Bayesian approach (GWAS-PW).

Finally, we investigated local regions of a shared genetic variant between the WMH subtypes and stroke (Table XV in the [Data Supplement](#)). A region on chromosome 7 (encompassing the PVWMH *NOS3* exonic SNP) exhibited shared genetic influence of all stroke with both phenotypes. Other regions of shared influence with all stroke were observed for PVWMH only. For the subtypes of stroke, significant regions were identified for DWMH and PVWMH, but none were found for both phenotypes except the chromosome 7 region for ischemic stroke (also identified for all stroke). Similar to the GW level correlation, a positive regional level genetic correlation was observed between the WMH subtypes and stroke (all stroke, all-ischemic, cardio-embolic and small vessel), by using HESS.<sup>27</sup>


## DISCUSSION

In our meta-analyses using all available individuals (n = 6654, phase II), PVWMH had significant

independent associations with loci containing genes implicated in large and SVD, as well as ischemic and deep hemorrhagic stroke suggesting a unique genetic and pathophysiological underpinning. Although our phase II GWAS were only slightly larger than the previous biggest GWAS on total WMH burden with 21 079 participants,<sup>21</sup> our detection rate of significant SNPs was substantially higher.<sup>18,19,21</sup> This improved detection may be the result of reduced heterogeneity by separately analyzing the DWMH and PVWMH phenotypes.

We identified 11 independent loci for PVWMH and one locus for DWMH. Significant genes associated with WMH for the first time in PVWMH include *CALCRL*, *VCAN*, *TSPAN*, and *NOS3*. Most genes and loci previously reported as significant in total WMH.<sup>28–32</sup> were now found to be associated with PVWMH alone, including *PLEKHG1*,<sup>22</sup> *SH3PXD2A*,<sup>25,28,33</sup> and *COL4A2*.<sup>33</sup> Similarly, genes viewed as potential candidates<sup>18,19,21</sup> in prior studies we now find to be significantly associated only with PVWMH, including *DYDC2* and *NEURL1*, as well as *NMT1*, *GALK1*, *H3F3B*, *UNK*, *UNC13D*, *EVPL*, *ICAL1*, *WDR12/CARF*, *NBEAL1*, and *EFEMP1*.

Many of these genes associated with PVWMH affect vascular function or vascular diseases, such as ischemic stroke or coronary artery disease. The *NOS3* gene is associated with coronary artery disease, migraine,



**Figure 2. A, Overlap between genome-wide significant SNPs ( $P < 5 \times 10^{-8}$ ) for deep white matter hyperintensities (DWMH) and periventricular white matter hyperintensities (PVWMH).**

**B and C,** Circos plots for chromosome 17 for both phenotypes, showing two identified regions for PVWMH (**B**) but only one for DWMH (**C**). Outer ring shows SNPs  $< 0.05$  with the most significant SNPs located towards the outermost ring. SNPs in high linkage disequilibrium (LD) with the independent significant SNPs in each locus are colored in red ( $r^2 > 0.8$ )-blue ( $r^2 > 0.2$ ); no LD (gray). Genomic risk loci are colored in dark blue (second layer). Genes are mapped by chromatin interaction (orange), eQTL (green), or both (red). **D,** Overlap between significant genes identified by MAGMA for both phenotypes.

AQ16

vascular dysfunction, SVD, and ischemic stroke.<sup>22,29,30,34</sup> *PLEKHG1* is associated with dementia and ischemic stroke,<sup>35</sup> and *SH3PXD2A* has been previously associated with total WMH and ischemic stroke.<sup>19,25</sup>

The most notable associated vascular gene is *COL4A2* that encodes for a subunit of type IV collagen, which has been associated with SVD, ischemic stroke, intracranial hemorrhage, and coronary artery disease.<sup>31,35–38</sup> It is a proposed therapeutic target for the prevention of intracranial hemorrhage.<sup>32,39</sup> The association of this vascular gene with PVWMH and deep intracerebral hemorrhage is suggestive of underlying regional gene effects of the *COL4A2* gene on the microvasculature affecting the risk of

vascular injury in the periventricular region. These include potential weakening of the structural integrity of the regional microvasculature by altered collagen type 4 structural integrity, dysregulated gene expression of *COL4A1* and *COL4A2*, and toxic cytosolic accumulations of COL4A2 within microvascular structural cells.<sup>40</sup> When comparing PVWMH and DWMH anatomy, these mechanisms may enhance the direct mechanical effects of hypertension, or the other stroke risk factors, on the unique microvascular structure of the PVWMH region that also has predicted higher ambient blood pressure.<sup>1,6,13</sup>

We also discovered a new set of putative PVWMH genes. These include: *TSPAN14*, which encodes one of

**Table 2. Thirty-Two Significant Genes Were Identified for PVWMH Using Gene-Based Tests ( $P < 2.66 \times 10^{-6}$ )**

Gene	CHR	START	STOP	N SNPs	N	P PVWMH	P DWMH
<i>WBP2</i>	17	73841780	73852588	28	24 682	$3.19 \times 10^{-26}$	$1.16 \times 10^{-21*}$
<i>TRIM65</i>	17	73876416	73893084	52	24 555	$7.73 \times 10^{-24}$	$9.12 \times 10^{-19*}$
<i>TRIM47</i>	17	73870242	73874656	13	24 185	$1.70 \times 10^{-23}$	$9.04 \times 10^{-19*}$
<i>RP11-552F3.12</i>	17	73894726	73926210	53	24 351	$2.15 \times 10^{-20}$	$1.76 \times 10^{-15*}$
<i>FBF1†</i>	17	73905655	73937221	55	24 338	$3.98 \times 10^{-17}$	$1.23 \times 10^{-13*}$
<i>GALK1†</i>	17	73747675	73761792	36	24 307	$6.34 \times 10^{-16}$	$3.23 \times 10^{-14*}$
<i>MRPL38</i>	17	73894724	73905899	21	24 481	$7.62 \times 10^{-15}$	$1.18 \times 10^{-13*}$
<i>UNC13D</i>	17	73823306	73840798	73	23 788	$3.10 \times 10^{-14}$	$1.22 \times 10^{-13*}$
<i>UNK</i>	17	73780681	73821886	120	22 768	$3.28 \times 10^{-13}$	$4.85 \times 10^{-10*}$
<i>H3F3B</i>	17	73772515	73781974	23	24 009	$4.43 \times 10^{-12}$	$1.41 \times 10^{-10*}$
<i>SH3PXD2A</i>	10	105348285	105615301	788	24 847	$8.43 \times 10^{-12}$	0.21731
<i>ACOX1</i>	17	73937588	73975515	151	24 198	$7.72 \times 10^{-11}$	$1.1 \times 10^{-9*}$
<i>EVPL</i>	17	74000583	74023533	67	24 582	$1.26 \times 10^{-10}$	$2.82 \times 10^{-14*}$
<i>PLEKHG1</i>	6	150920999	151164799	1022	24 922	$1.59 \times 10^{-10}$	0.011765
<i>WDR12†</i>	2	203739505	203879521	322	23 753	$2.53 \times 10^{-10}$	0.00104
<i>ICA1L†</i>	2	203640690	203736708	224	23 843	$8.44 \times 10^{-10}$	0.001301
<i>CARF†</i>	2	203776937	203851786	157	24 076	$2.41 \times 10^{-9}$	0.001763
<i>NMT1†</i>	17	43128978	43186384	221	24 766	$7.18 \times 10^{-8}$	0.00034
<i>CDK3†</i>	17	73996987	74002080	12	24 433	$8.54 \times 10^{-8}$	$1.82 \times 10^{-9*}$
<i>OBFC1†</i>	10	105642300	105677963	99	25 461	$1.41 \times 10^{-7}$	0.054127
<i>NOS3†</i>	7	150688083	150711676	58	24 608	$1.73 \times 10^{-7}$	0.000371
<i>DCAKD†</i>	17	43100708	43138473	111	25 229	$2.60 \times 10^{-7}$	0.000363
<i>DYDC2†</i>	10	82104501	82127829	91	25 050	$2.88 \times 10^{-7}$	0.003460
<i>NBEAL1</i>	2	203879602	204091101	367	23 413	$3.83 \times 10^{-7}$	0.040539
<i>NEURL1</i>	10	105253736	105352309	296	25 038	$4.84 \times 10^{-7}$	0.098303
<i>MAT1A†</i>	10	82031576	82049440	66	25 295	$4.90 \times 10^{-7}$	0.002421
<i>TSPAN14†</i>	10	82213922	82292879	213	24 731	$6.73 \times 10^{-7}$	0.006605
<i>CALCRL†</i>	2	188207856	188313187	278	24 309	$7.87 \times 10^{-7}$	0.000574
<i>KLHL24†</i>	3	183353356	183402265	207	24 356	$1.29 \times 10^{-6}$	0.002571
<i>POLR2F†</i>	22	38348614	38437922	105	23 525	$1.94 \times 10^{-6}$	0.252540
<i>VCAN†</i>	5	82767284	82878122	316	24 248	$2.52 \times 10^{-6}$	0.065044
<i>COL4A2</i>	13	110958159	111165374	1140	24 876	$2.61 \times 10^{-6}$	0.365300


Chr indicates chromosome; PVWMH, periventricular white matter hyperintensities; and DWMH, deep white matter hyperintensities.

\*Thirteen of these genes (chr 17) were also significant for DWMH.

†Those loci bolded have not been previously associated with total WMH.

the tetraspanins which organize a network of interactions referred to as the tetraspanin web, ADAM10<sup>41</sup> metalloprotease that cleaves the precursor of cell surface proteins,<sup>41</sup> *KLHL24* encodes a ubiquitin ligase substrate receptor,<sup>42</sup> *VCAN* encodes a large chondroitin sulfate proteoglycan that is found in the extracellular matrix. In a recent meta-analysis, *VCAN* was associated with white matter microstructural integrity.<sup>43</sup> These candidate genes for PVWMH may influence the immediate tissues surrounding microvessels and may contribute to SVD-associated biological changes.

The only significant locus observed for DWMH was the previously reported total WMH 17q25.1 locus,<sup>18,19,21,22</sup> which was also found for PVWMH. This locus contained the SNPs with the largest effect sizes for both phenotypes. The top genome-wide significant hits for DWMH and PVWMH (17q25.1) were either identical with the SNP recently reported by Traylor et al<sup>22</sup> for total WMH (PVWMH rs3744020) or in high linkage disequilibrium ( $R^2 > 0.9$ ) with the previously identified top ranked SNPs in the same locus (rs3744028, Fornage et al,<sup>18</sup> rs7214628, Verhaaren et al<sup>21</sup>). Our identified SNPs were



**Figure 3. Genetic correlations (rg) between deep white matter hyperintensities (DWMH), periventricular white matter hyperintensities (PVWMH), Alzheimer disease (AD), and stroke phenotypes.**

Horizontal bars represent SE, and the size of the square corresponds precision. ICH indicates intracranial hemorrhage; and SVD, small vessel disease stroke.

only in moderate linkage disequilibrium ( $R^2 \leq 0.396$ ) with the top SNP (rs3760128) identified in a recent exome association analysis.<sup>19</sup> All of these SNPs fall within or between the previously reported *TRIM47* and *TRIM65* genes.<sup>18,21,22,35</sup> This gene-rich locus contains genes that influence glial cell proliferation and have been hypothesized to influence gliosis, which is a histological and magnetic resonance imaging marker of microvascular injury.<sup>1</sup> It includes previously identified total WMH genes, such as *TRIM47/TRIM65* (glial proliferation, astrocytoma's),<sup>18,21</sup> *ACOX1* (cell replication, hepatic cancer)<sup>18,19,21</sup> and *MRPL38* (protein synthesis).<sup>19</sup> Genes associated with neuronal injury or neurodegenerative disorders are also found in the 17q25.1 locus, including *CDK3* (neuronal cell death in stroke),<sup>44</sup> *H3F3B* (schizophrenia pathogenesis) and *GALK1* (galactosemia).<sup>45</sup> Interestingly, 2 genome-wide significant intronic *UNC13D* SNPs identified in this study and reported previously for total WMH burden,<sup>21</sup> rs9894244 and rs7216615, have been reported as eQTLs for *GALK1* and *H3F3B*, respectively.<sup>46</sup> The PVWMH specific loci also contained genes that potentially influence astrocytic function and gliosis, several previously reported for total WMH. These include *NBEAL1*,<sup>19,21</sup> *WDR12*,<sup>19</sup> *NEURL1*,<sup>18,19,21</sup> *CARF*,<sup>47</sup> and *EFEMP1*.<sup>37</sup> Newly identified PVWMH genes potentially affecting astrocytic functioning include *NMT1*,<sup>48</sup> *ICA1L*,<sup>49</sup> *POLR2F*, *OBFC1*, and *DYDC2*.

Shortcomings of this study include the potential variability due to the different WMH extraction algorithms used, with a minority of samples using visual ratings. However, this is a common problem encountered in this type of study.<sup>18,19,21</sup> Although our results suggest improved power and reduction in potential bias through the discrimination of PVWMH from DWMH, the Euclidean methodology used by the majority of studies undoubtedly missed PVWMH lesions outside this boundary. The majority of the participants in this study were white, and hence these results may not apply to other ethnicities. Sex differences have been previously reported but were not examined in the current study.<sup>50</sup> For the phase II meta-analysis, we did not have an independent replication cohort. Older adults were included in this study, and the majority of

participants had both DWMH and PVWMH and not one or the other. However, selection of individuals with only one subtype of these lesions present may be more appropriate to identify differences but would only be possible in younger cohorts. Future studies should aim to address these shortcomings, including continuing to improve and harmonize WMH measurement methods but also using consistent DWMH and PVWMH measurement methods across studies.

## SUMMARY/CONCLUSIONS

Our study confirms PVWMH and DWMH have distinct and shared genetic architecture. Genetic analyses indicated PVWMH was more associated with ischemic stroke and vascular function (*PLEKHG1*, *SH3PXD2*, *COL4A2*, *CALCRL*, *VCAN*, *NOS3*), whereas DWMH loci were implicated in vascular, astrocyte and neuronal function (*TRIM47/TRIM65*, *ACOX1*, *MRPL38*, *H3F3B*, *GALK1*, *UNC13D*, *GALK1*). New genes for PVWMH, potentially affecting the extravascular connective tissue, were also identified (*TSPAN14*, *ADAM10*, *KLHL24*, *VCAN*). Our study confirms that PVWMH and DWMH are distinct neuroimaging classifications and identifies new candidate genes associated with PVWMH only.

## ARTICLE INFORMATION

Received September 11, 2019; final revision received March 30, 2020; accepted April 27, 2020.

### Affiliations

From the Mathematics and Statistics, Murdoch University, Perth, Australia (N.J.A.); Centre for Healthy Brain Ageing, School of Psychiatry (K.A.M., W.W., H.B., J.J., A.T., J.T., P.S.S.), School of Medical Sciences (J.B.K., P.R.S.), Dementia Centre for Research Collaboration (H.B.), and Department of Developmental Disability Neuropsychiatry, School of Psychiatry (J.T.), University of New South Wales, Sydney, Australia; Neuroscience Research Australia, Sydney, Australia (K.A.M., P.R.S., A.T.); University Bordeaux, Inserm, Bordeaux Population Health Research Center, France (M.S., C.T., S.D.); Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (M.J.K., D.V., N.A., G.V.R., M.W.V., C.M.v.D., M.A.I., H.H.H.A.); Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-Universität LMU Munich, Germany (R.M., M.D.); Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, UT Health San Antonio, San Antonio, TX (C.L.S., S.S.); The Framingham Heart Study, MA (C.L.S., A.S.B., J.R.R., S.S.); Department of Neurology (C.L.S., A.S.B., J.R.R.,



S.S.) and Department of Psychiatry and Biomedical Genetics Section (M.A.L.), Boston University School of Medicine, MA; GeneSTAR Research Program (L.R.Y., B.G.K., L.C.B., P.A.N.), Department of Neurology, Cerebrovascular and stroke Division (R.G.), and Departments of Neurology, Critical Care Medicine, Neurosurgery (P.A.N.), Johns Hopkins University School of Medicine, Baltimore, MD; Icelandic Heart Association, Kopavogur (V.G.G., S.S.); University of Iceland, Reykjavik, Iceland (V.G.G., A.V.S.); John P. Hussman Institute for Human Genomics (N.D.D.), Dr. John T. Macdonald Foundation Department of Human Genetics (R.L.S.), Department of Public Health Sciences, Miller School of Medicine (R.L.S.), Department of Neurology, Miller School of Medicine (R.L.S.), Evelyn F. McKnight Brain Institute, Department of Neurology (R.L.S.), University of Miami, FL; Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, BC, Canada (L.T.E.); Wellcome Centre for Integrative Neuroimaging (WIN FMRIB) (L.T.E., F.A.-A., L.G., M.J., S.M.S.) and Nuffield Department of Population Health (C.M.v.D.), University of Oxford, United Kingdom; Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Austria (E.H., R.S.); Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Austria (E.H.); Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA (J.B., B.P., W.L.); Mark and Mary Neuroimaging and Informatics Institute, Keck School of Medicine of USC, University of Southern California, Marina del Rey (N.J., Q.Y.); Department of Biostatistics, Boston University School of Public Health, Boston, MA (S.L., M.A.L., A.S.B.); National Center for PTSD: Behavioral Science Division, VA Boston Healthcare System, Boston, MA (M.A.L.); Centre for Cognitive Ageing and Cognitive Epidemiology, Psychology (M.L., I.J.D., D.C.M.L.), Division of Neuroimaging Sciences, Brain Research Imaging Centre, University of Edinburgh, United Kingdom (J.M.V.); Institute for Medical Informatics, Statistics and Epidemiology (M.S.) and Collaborative Research Center 1052 Obesity Mechanisms, Faculty of Medicine, University of Leipzig, Germany (V.A.W.); LIFE Research Center for Civilization Disease, Leipzig, Germany (M.S.); Department of Internal Medicine, Section of Gerontology and Geriatrics (S.S.T.), Department of Cardiology (S.S.T.), Department of Radiology (J.v.d.G.), and Department of Cardiology (J.W.J.), Leiden University Medical Center, the Netherlands; Brown Foundation Institute of Molecular Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, TX (R.X., M.F.); National Ageing Research Institute, Parkville, Victoria, Australia (D.A.); Academic Unit for Psychiatry of Old Age, University of Melbourne, St George's Hospital, Kew, Australia (D.A.); Lille University, Inserm, Institut Pasteur de Lille, RID-AGE - Risk Factors and Molecular Determinants of Aging-Related Diseases and Labex Distalz, France (P.A.); Department of Psychiatry (C.F.-N.), Center for Behavior Genetics of Aging (C.F.-N.), Center for Behavior Genetics of Aging (W.S.K.), and Department of Psychiatry (W.S.K.), University of California, San Diego, La Jolla, CA; Gottfried Schatz Research Center (for Cell Signaling, Metabolism and Aging), Medical University of Graz, Austria (P.G.G., H.S.); Department of Radiology, Mayo Clinic, Rochester, MN (C.R.J.J.); Brain and Mind Centre - The University of Sydney, Camperdown, NSW, Australia (J.B.K.); Department of Neurology, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (L.L., V.A.W.); Imaging of Dementia and Aging (IDeA) Laboratory, Department of Neurology, University of California-Davis, Davis, CA (P.M.); Statistical Genetics and Methods at Regeneron Pharmaceuticals, Inc, New York, NY (J.M.); Centre for Clinical Brain Sciences, University of Edinburgh & Brain Research Imaging Centre, University of Edinburgh, United Kingdom (M.E.B.); Institut des Maladies Neurodégénératives, University of Bordeaux, France (B.M.); Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Austria (L.P.); Department of Radiology and Nuclear Medicine (G.V.R., M.W.V., H.H.H.A.) and Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands (H.H.H.A.); Department of Neurology, Max-Planck-Institute for Human Cognitive and Brain Sciences, Leipzig, Germany (M.L.S., A.V.); Day Clinic for Cognitive Neurology, University Hospital Leipzig, Germany (M.L.S., A.V.); Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom (D.J.S.); CHU de Bordeaux, Public Health Department, Medical information Department, Bordeaux, France (C.T.); Queensland Brain Institute (M.J.W.) and Centre for Advanced Imaging (M.J.W.), The University of Queensland, St Lucia, QLD, Australia; Neuroradiology Department, Department of Clinical Neurosciences, Western General Hospital, Edinburgh, United Kingdom (Z.M.); Department of Neuromedicine and Movement Science (A.K.H.) and Department of Radiology and Nuclear Medicine (A.K.H.), Norwegian University of Science and Technology, Trondheim, Norway; Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, the Netherlands (J.W.J.); German Center for Neurodegenerative Diseases, Munich, Germany (M.D.); Munich Cluster for Systems Neurology (SyNergy), Germany (M.D.); National Institute of Neurological Disorders and Stroke (C.B.W.), Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program (L.L.), and Critical Care Medicine Department (P.A.N.), National Institutes of Health, Bethesda, MD; Department of Geriatric Medicine, Memory Impairment and Neurodegenera-

tive Dementia (MIND) Center, University of Mississippi Medical Center, Jackson (T.H.M.); Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, Australia (P.S.S.); Alzheimer's Disease Center and Imaging of Dementia and Aging (IDeA) Laboratory, Department of Neurology and Center for Neuroscience University of California at Davis (C.D.); Human Genetics Center, School of Public Health UT, Houston, TX (M.F.); and Department of Neurology, CHU de Bordeaux (University Hospital), Bordeaux, France (S.D.).

## Acknowledgments

See in the [Data Supplement](#).

## Sources of Funding

This work is supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health, R01AG059874, P41EB015922, R56AG058854, U54 EB020403, R01AG022381. Medical Research Council, Age UK, Scottish Funding Council, Row Fogo Trust, The Wellcome Trust, Age UK, Cross Council Lifelong Health and Wellbeing Initiative, Leverhulme Trust, National Institute for Health Research, Biotechnology and Biological Sciences Research Council, UK Medical Research Council, Icelandic Heart Association, and the Althingi, Austrian Science Fund (FWF), Australian National Health and Medical Research Council, Austrian National Bank, Anniversary Fund, European Commission FP6 STRP, European Community's 5th and 7th Framework Program, Netherlands Organization for Scientific Research, Netherlands Consortium for Healthy Aging, Russian Foundation for Basic Research, Russian Federal Agency of Scientific Organizations, Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology, Norwegian National Advisory Unit for functional magnetic resonance imaging (MRI), Leipzig Research Center for Civilization Diseases (LIFE), Bristol-Myers Squibb, Netherlands Heart Foundation, French National Research Agency (ANR), Foundation Leducq, Joint Programme of Neurodegenerative Disease research, Bordeaux University, Institut Pasteur de Lille, the labex DISTALZ and the Centre National de Génotypage. Deutsche Forschungsgesellschaft (DFG) no. WI 3342/3-1 and grants from European Union, European Regional Development Fund, Free State of Saxony within the framework of the excellence initiative, LIFE-Leipzig Research Center for Civilization Diseases no. 100329290, 713-241202, 14505/2470, 14575/2470. Max Planck Society, State of Saxony, Brain Foundation, Bristol-Myers Squibb, National Health and Medical Research Council (NHMRC) of Australia, NHMRC of Australia, Parkinson's UK; Medical Research Council - Dementias Platform UK. Full details of funding support for each cohort are detailed in the [Data Supplement](#).

## Disclosure

Dr Marchini is an employee of, and owns stock and stock options for, Regeneron Pharmaceuticals; Dr Sachdev received personal fees from Biogen; Henry Brodaty, Advisory Board member, Nutricia Australia; ~~Philippe Amouyel, advisor for Foundation Alzheimer, Occupational medicine, Oil company, and Genoscreen Biotech company; Alzheimer's Foundation, Occupational Medicine, Oil company, Genoscreen personal fees, Biotech company;~~ Christine Fennema-Notestine, received funding from National Institutes of Health Grants ~~NIH R01AG022381; Dr Gottesman, American Academy of Neurology, Associate Editor, Neurology; Dr Thompson, funded by National Institutes of Health (NIH) grant U54 EB020403 and received partial research support from Biogen, Inc,~~ Dr DeCarli, consultant to Novartis; Markus Scholz disclosed Pfizer, Inc, grants; Ralph Sacco, grant support from Boehringer Ingelheim, National Institute of Neurological Disorders and Stroke Grants; ~~Dr Jahanshad received funding from the NIH grants, NIH R01AG059874, NIH R01AG059874;~~ Dr Wardlaw, grant support from the Medical Research Council, Age UK, Scottish Funding Council, and Row Fogo Trust during the conduct of the study and grant support from Fondation Leducq, Wellcome Trust, EHF, Heart Health Stroke Scotland, British Heart Foundation, Stroke Association, and the Scottish Brain Research Centre. Dr Marchini reports no disclosures outside the submitted work. The other authors report no conflicts.

## REFERENCES

1. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al; Standards for Reporting Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol*. 2013;12:822-838. doi: 10.1016/S1474-4422(13)70124-8
2. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM; Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase

- stroke risk in the general population: the Rotterdam Scan Study. *Stroke*. 2003;34:1126–1129. doi: 10.1161/01.STR.0000068408.82115.D2
3. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JGG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *J Neurol Neurosurg Psychiatry*. 2011;82:126–135. doi: 10.1136/jnnp.2009.204685
  4. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol*. 2013;12:483–497. doi: 10.1016/S1474-4422(13)70060-7
  5. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, Radner H, Lechner H. Pathologic correlates of incidental MRI white matter signal hyperintensities. *Neurology*. 1993;43:1683–1689. doi: 10.1212/wnl.43.9.1683
  6. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med*. 2003;348:1215–1222. doi: 10.1056/NEJMoa022066
  7. Griffanti L, Jenkinson M, Suri S, Zsoldos E, Mahmood A, Filippini N, Sexton CE, Topiwala A, Allan C, Kivimäki M, et al. Classification and characterization of periventricular and deep white matter hyperintensities on MRI: a study in older adults. *Neuroimage*. 2018;170:174–181. doi: 10.1016/j.neuroimage.2017.03.024
  8. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, et al; MRC Cognitive Function and Ageing Neuropathology Study Group. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. *Stroke*. 2006;37:1391–1398. doi: 10.1161/01.STR.00000221308.94473.14
  9. Albrecht M, Zitta K, Bein B, Wennemuth G, Broch O, Renner J, Schuett T, Lauer F, Maahs D, Hummitzsch L, et al. Remote ischemic preconditioning regulates HIF-1 $\alpha$  levels, apoptosis and inflammation in heart tissue of cardiosurgical patients: a pilot experimental study. *Basic Res Cardiol*. 2013;108:314. doi: 10.1007/s00395-012-0314-0
  10. Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, Coker LH, Shibata DK, Knopman DS, Jack CR, Mosley TH Jr. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. *Stroke*. 2010;41:3–8. doi: 10.1161/STROKEAHA.109.566992
  11. Krishnan MS, O'Brien JT, Firbank MJ, Pantoni L, Carlucci G, Erkinjuntti T, Wallin A, Wahlund LO, Scheltens P, van Straaten ECW, et al; LADIS Group. Relationship between periventricular and deep white matter lesions and depressive symptoms in older people. The LADIS Study. *Int J Geriatr Psychiatry*. 2006;21:983–989. doi: 10.1002/gps.1596
  12. Kreisel SH, Blahak C, Bärner H, Inzitari D, Pantoni L, Poggesi A, Chabriot H, Erkinjuntti T, Fazekas F, Ferro JM, et al. Deterioration of gait and balance over time: the effects of age-related white matter change—the LADIS study. *Cerebrovasc Dis*. 2013;35:544–553. doi: 10.1159/000350725
  13. Blanco PJ, Müller LO, Spence JD. Blood pressure gradients in cerebral arteries: a clue to pathogenesis of cerebral small vessel disease. *Stroke Vasc Neurol*. 2017;2:108–117. doi: 10.1136/svn-2017-000087
  14. De Reuck J. The human periventricular arterial blood supply and the anatomy of cerebral infarctions. *Eur Neurol*. 1971;5:321–334. doi: 10.1159/000114088
  15. Potter GM, Doubal FN, Jackson CA, Chappell FM, Sudlow CL, Dennis MS, Wardlaw JM, Eyler LT, Neale MC, Xian H. Enlarged perivascular spaces and cerebral small vessel disease. *Int J Stroke*. 2015;10:376–381. doi: 10.1111/ijs.12054
  16. Sachdev PS, Thalamuthu A, Mather KA, Ames D, Wright MJ, Wen W; OATS Collaborative Research Team. White matter hyperintensities are under strong genetic influence. *Stroke*. 2016;47:1422–1428. doi: 10.1161/STROKEAHA.116.012532
  17. Fennema-Notestine C, McEvoy LK, Notestine R, Panizzon MS, Yau WW, Franz CE, Lyons MJ, et al. White matter disease in midlife is heritable, related to hypertension, and shares some genetic influence with systolic blood pressure. *Neuroimage Clin*. 2016;12:737–745. doi: 10.1016/j.nicl.2016.10.001
  18. Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, Sigurdsson S, Lumley T, DeStefano AL, Fazekas F, et al. Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. *Ann Neurol*. 2011;69:928–939. doi: 10.1002/ana.22403
  19. Jian X, Satizabal CL, Smith AV, Wittfeld K, Bis JC, Smith JA, Hsu FC, Nho K, Hofer E, Hagenaars SP, et al; neuroCHARGE Working Group. Exome chip analysis identifies low-frequency and rare variants in MRPL38 for white matter hyperintensities on brain magnetic resonance imaging. *Stroke*. 2018;49:1812–1819. doi: 10.1161/STROKEAHA.118.020689
  20. Verhaaren BF, de Boer R, Vernooij MW, Rivadeneira F, Uitterlinden AG, Hofman A, Krestin GP, van der Lugt A, Niessen WJ, Breteler MMB, et al. Replication study of chr17q25 with cerebral white matter lesion volume. *Stroke*. 2011;42:3297–3299. doi: 10.1161/STROKEAHA.111.623090
  21. Verhaaren BF, Debette S, Bis JC, Smith JA, Ikram MK, Adams HH, Beecham AH, Rajan KB, Lopez LM, Barral S, et al. Multiethnic genome-wide association study of cerebral white matter hyperintensities on MRI. *Circ Cardiovasc Genet*. 2015;8:398–409. doi: 10.1161/CIRCGENETICS.114.000858
  22. Traylor M, Tozer DJ, Croall ID, Lisiecka-Ford DM, Olorunda AO, Boncoraglio G, et al; International Stroke Genetics Consortium. Genetic variation in PLEKHG1 is associated with white matter hyperintensities (n = 11,226). *Neurology*. 2019;92:e749–e757. doi: 10.1212/WNL.0000000000006952
  23. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190–2191. doi: 10.1093/bioinformatics/btq340
  24. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al; Schizophrenia Working Group of the Psychiatric Genomics Consortium. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47:291–295. doi: 10.1038/ng.3211
  25. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al; AFGen Consortium; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium; International Genomics of Blood Pressure (iGEN-BP) Consortium; INVENT Consortium; STARNET; BioBank Japan Cooperative Hospital Group; COMPASS Consortium; EPIC-CVD Consortium; EPIC-InterAct Consortium; International Stroke Genetics Consortium (ISGC); METASTROKE Consortium; Neurology Working Group of the CHARGE Consortium; NINDS Stroke Genetics Network (SiGN); UK Young Lacunar DNA Study; MEGASTROKE Consortium. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet*. 2018;50:524–537. doi: 10.1038/s41588-018-0058-3
  26. Pickrell JK, Berisa T, Liu JZ, Séguérel L, Tung JY, Hinds DA. Detection and interpretation of shared genetic influences on 42 human traits. *Nat Genet*. 2016;48:709–717. doi: 10.1038/ng.3570
  27. Shi H, Mancuso N, Spendlove S, Pasaniuc B. Local genetic correlation gives insights into the shared genetic architecture of complex traits. *Am J Hum Genet*. 2017;101:737–751. doi: 10.1016/j.ajhg.2017.09.022
  28. Traylor M, Zhang CR, Adib-Samii P, Devan WJ, Parsons OE, Lanfranconi S, et al; International Stroke Genetics Consortium. Genome-wide meta-analysis of cerebral white matter hyperintensities in patients with stroke. *Neurology*. 2016;86:146–153. doi: 10.1212/WNL.0000000000002263
  29. Chen XJ, Qiu CG, Kong XD, Ren SM, Dong JZ, Gu HP, et al. The association between an endothelial nitric oxide synthase gene polymorphism and coronary heart disease in young people and the underlying mechanism. *Mol Med Rep*. 2018;17:3928–3934. doi: 10.3892/mmr.2017.8314
  30. Bastian C, Zaleski J, Stahon K, Parr B, McCray A, Day J, et al. NOS3 Inhibition confers post-ischemic protection to young and aging white matter integrity by conserving mitochondrial dynamics and mito-2 levels. *J Neurosci*. 2018;38:6247–6266. doi: 10.1523/JNEUROSCI.3017-17.2018
  31. Rannikmäe K, Sivakumaran V, Millar H, Malik R, Anderson CD, Chong M, et al; Stroke Genetics Network (SiGN), METASTROKE Collaboration, and International Stroke Genetics Consortium (ISGC). COL4A2 is associated with lacunar ischemic stroke and deep ICH: Meta-analyses among 21,500 cases and 40,600 controls. *Neurology*. 2017;89:1829–1839. doi: 10.1212/WNL.0000000000004560
  32. Murray LS, Lu Y, Taggart A, Van Regemorter N, Vilain C, Abramowicz M, et al. Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke. *Hum Mol Genet*. 2014;23:283–292. doi: 10.1093/hmg/ddt418
  33. Traylor M, Malik R, Nalls MA, Colclaciu I, Radmanesh F, Thorleifsson G, et al; METASTROKE, UK Young Lacunar DNA Study, NINDS Stroke Genetics Network, Neurology Working Group of the CHARGE Consortium; International Stroke Genetics Consortium. Genetic variation at 16q24.2 is associated with small vessel stroke. *Ann Neurol*. 2017;81:383–394. doi: 10.1002/ana.24840
  34. Malik R, Rannikmäe K, Traylor M, Georgakis MK, Sargurupremraj M, Markus HS, et al; MEGASTROKE consortium and the International Stroke Genetics Consortium. Genome-wide meta-analysis identifies 3 novel loci associated with stroke. *Ann Neurol*. 2018;84:934–939. doi: 10.1002/ana.25369
  35. Traylor M, Lewis CM. Genetic discovery in multi-ethnic populations. *Eur J Hum Genet*. 2016;24:1097–1098. doi: 10.1038/ejhg.2016.38

36. Rannikmäe K, Davies G, Thomson PA, Bevan S, Devan WJ, Falcone GJ, et al; METASTROKE Consortium; CHARGE WMH Group; ISGC ICH GWAS Study Collaboration; WMH in Ischemic Stroke GWAS Study Collaboration; International Stroke Genetics Consortium. Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. *Neurology*. 2015;84:918–926. doi: 10.1212/WNL.0000000000001309
37. Yang L, Ou B, Xia X, Kuang Y, Li J, Fan K, et al. Impact of interaction between the G870A and EFEMP1 gene polymorphism on glioma risk in Chinese Han population. *Oncotarget*. 2017;8:37561–37567. doi: 10.18632/oncotarget.16581
38. Verbeek E, Meuwissen ME, Verheijen FW, Govaert PP, Licht DJ, Kuo DS, et al. COL4A2 mutation associated with familial porencephaly and small-vessel disease. *Eur J Hum Genet*. 2012;20:844–851. doi: 10.1038/ejhg.2012.20
39. Kuo DS, Labelle-Dumais C, Gould DB. COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. *Hum Mol Genet*. 2012;21(R1):R97–110. doi: 10.1093/hmg/dds346
40. Jeanne M, Labelle-Dumais C, Jorgensen J, Kauffman WB, Mancini GM, Favor J, et al. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. *Am J Hum Genet*. 2012;90:91–101. doi: 10.1016/j.ajhg.2011.11.022
41. Saint-Pol J, Eschenbrenner E, Dornier E, Boucheix C, Charrin S, Rubinstein E. Regulation of the trafficking and the function of the metalloprotease ADAM10 by tetraspanins. *Biochem Soc Trans*. 2017;45:937–944. doi: 10.1042/BST20160296
42. Has C. The "Kelch" Surprise: KLHL24, a new player in the pathogenesis of skin fragility. *J Invest Dermatol*. 2017;137:1211–1212. doi: 10.1016/j.jid.2017.02.011
43. Rutten-Jacobs LCA, Tozer DJ, Duering M, Malik R, Dichgans M, Markus HS, et al. Genetic Study of white matter integrity in UK biobank (N=8448) and the overlap with stroke, depression, and dementia. *Stroke*. 2018;49:1340–1347. doi: 10.1161/STROKEAHA.118.020811
44. Osuga H, Osuga S, Wang F, Fetni R, Hogan MJ, Slack RS, et al. Cyclin-dependent kinases as a therapeutic target for stroke. *Proc Natl Acad Sci U S A*. 2000;97:10254–10259. doi: 10.1073/pnas.170144197
45. Timmers I, Zhang H, Bastiani M, Jansma BM, Roebroek A, Rubio-Gozalbo ME. White matter microstructure pathology in classic galactosemia revealed by neurite orientation dispersion and density imaging. *J Inherit Metab Dis*. 2015;38:295–304. doi: 10.1007/s10545-014-9780-x
46. Wild PS, Felix JF, Schillert A, Teumer A, Chen MH, Leening MJG, et al. Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. *J Clin Invest*. 2017;127:1798–1812. doi: 10.1172/JCI84840
47. Tao X, West AE, Chen WG, Corfas G, Greenberg ME. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. *Neuron*. 2002;33:383–395. doi: 10.1016/s0896-6273(01)00561-x
48. Lu Y, Selvakumar P, Ali K, Shrivastav A, Bajaj G, Resch L, et al. Expression of N-myristoyltransferase in human brain tumors. *Neurochem Res*. 2005;30:9–13. doi: 10.1007/s11064-004-9680-9
49. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. *Nat Genet*. 2001;29:166–173. doi: 10.1038/ng1001-166
50. Sachdev P, Chen X, Wen W. White matter hyperintensities in mid-adult life. *Curr Opin Psychiatry*. 2008;21:268–274. doi: 10.1097/YCO.0b013e3282f945d5

# AUTHOR QUERIES


***Authors please note: Authors are responsible for any page charges as outlined in the acceptance letter or as indicated on the Instructions for Authors (<https://www.ahajournals.org/ATVc/revised-accepted-manuscripts>). Unless you have selected open access for your article, or it is otherwise noted on the acceptance letter, page charges are as follows: \$70 per black and white page (print articles only) or \$35 per page (online-only articles only). For each color page (print only), please add \$653/page. If there are any concerns regarding these charges, these should be addressed within 48 hours of receiving the s-proof. Author(s) will be invoiced for all color and page charges post publication. If you have selected open access for your article, please refer to details in the queries below.***


## AUTHOR PLEASE ANSWER ALL QUERIES


- AQ1–We have changed “etiology” to “cause” in the article title and where used, per style. Please check and confirm whether the changes are appropriate. Please note only those terms that are used 5 times or more can be abbreviated, except trial names and proteins, which should be expanded at first use but then can be abbreviated throughout regardless of how many times they appear. **appropriate**
- AQ2–Please turn to page 3 of your proof and review the running head, which will appear in the upper right-hand margins of odd-numbered pages. Running heads must be 50 or fewer characters in length, including spaces and punctuation. If your original short title was longer than 50 characters, we may have shortened it. Please modify if necessary (but observe our length guidelines). **appropriate**
- AQ3–Please confirm that all authors are included in the correct order in the byline and that all names are spelled correctly, including special characters, accents, middle initials, and degrees, if applicable. For indexing purposes, confirm author names have been correctly identified as given names (blue), surnames (red), and suffixes (black). Color in the byline will not appear on the final published version. Note that journal style discourages listing honorary degrees (FAHA, FRCP, etc.) in the byline; please delete such degrees from the author byline.][AQ: Please check the author name: Thomas H. Mosley. **modified in the manuscript**
- AQ4–Gene designations are italicized when referring to the gene or an allele but not when referring to the gene product. Please check and make appropriate corrections throughout the article where necessary. **appropriate**
- AQ5–Please define LDSC in abstract and text. **8**
- AQ6–Key words may have been edited to match the US National Library of Medicine's Medical Subject Headings (<http://www.nlm.nih.gov/mesh/MBrowser.html>). If they need modification, please limit the total number of key words to 7. **appropriate**
- AQ7–Please note, per style, “N” should be used to indicate total number of units in a study and “n” should indicate the units in a subgroup of the study. Please confirm that these were handled




appropriately throughout the article. Example: “Of the patients admitted from the emergency department (N=127), the most frequent admission diagnosis was unstable angina (n=38)”.


AQ8–Please define ICV, MEGASTROKE, HESS, GWAS-PW, METAL, QC, TRIM47/TRIM 65, ACOX1, MRPL38, H3F3B, HUNT, LBC and AGES in text, if applicable.  appropriate


AQ9–Please define SNP in text and tables 1 and 2 and figures 1 and 2.  Now defined in text


AQ10–“African American” has been changed to “black”, where used, per journal style. If you intended “African American” to identify only Americans specifically of African ancestry, and you feel this stylistic change has been applied incorrectly, please note this in your corrections, and we will revert to the original term used.  appropriate

AQ11–Please review the typeset tables carefully against copies of the originals to verify accuracy of editing and typesetting.  appropriate


AQ12–Please note that per style bold is not allowed in tables. Hence, please provide the significance of the bold values (indicated with \* and †) in the footnote of Tables 1 and 2.][AQ: Please define POS in Table 1.  modified in manuscript


AQ13–Per style, use of the word “panel” is not allowed for figure part labels. Hence, it has been deleted where used. Please check and confirm.  appropriate


AQ14–According to journal style figure labels (A, B, left, right, etc) cannot appear in the first sentence of the figure legend. Please provide a general first sentence for the figure legend that does not include any figure labels.  modified in the manuscript


AQ15–If you have color in your proof, please indicate whether you approve the color charge by returning the color agreement with your corrections. The color agreement can be found at <http://links.lww.com/str/A2>. The rate is \$653 per 1 printed color page. If you prefer black and white figures, please indicate so on your proof corrections. If you have any questions, please contact PE-Stroke@wolterskluwer.com.  No color, black and white only


AQ16–Please define MAGMA in Figure 2, if applicable.  appropriate as is


AQ17–Please define eQTL in text and Figure 1.  expression quantitative trait loci in text only


AQ18–Per style, quotations should not be used for emphasis. Hence, it has been removed where used. Please confirm if the changes made are correct.  appropriate


AQ19–Per style, use of “and/or” is not allowed. Hence, it has been changed to “or” in the sentence “Genes associated with neuronal injury or neurodegenerative disorders...” Please confirm whether the change made to the sentence is appropriate.  appropriate

AQ20–Please check the edits made and provide department or division details, if any, for the affiliations, if not listed already.  modified in the proofed manuscript

AQ21–Please confirm that all authors’ institutional affiliations (including city/state/country locations) are correct as shown in the affiliations footnote.  modified in proof manuscript

AQ22–Please carefully review any Acknowledgments, Sources of Funding, and/or Disclosures listed at the end of the manuscript (before the References), and confirm that they are accurate and complete for all authors.  modified in the manuscript

AQ23–Please define EPSRC and NIA in Disclosures.  Engineering and Physical Sciences Research Council EPSRC NIA is deleted

AQ24–We’ve identified that figure 1 are low resolution and could result in poor-quality graphics in the final publication. Please send higher-resolution versions of these figures, or approve to proceed with the figures as shown in your proof.  Attached new high def image